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Abstract
Background: GSAO (4-(N-(S-glutathionylacetyl)amino) phenylarsonous acid) and PENAO (4-(N-(S-
penicillaminylacetyl)amino) phenylarsonous acid) are tumour metabolism inhibitors that target adenine nucleotide
translocase (ANT) of the inner-mitochondrial membrane. Both compounds are currently being trialled in patients
with solid tumours. The trivalent arsenical moiety of GSAO and PENAO reacts with two matrix facing cysteine
residues of ANT, inactivating the transporter. This leads to proliferation arrest and death of tumour and tumour-
supporting cells.
Results: The two reactive ANT cysteine residues have been identified in this study by expressing cysteine mutants
of human ANT1 in Saccharomyces cerevisiae and measuring interaction with the arsenical moiety of GSAO and
PENAO. The arsenic atom of both compounds cross-links cysteine residues 57 and 257 of human ANT1.
Conclusions: The sulphur atoms of these two cysteines are 20 Å apart in the crystal structures of ANT and the
optimal spacing of cysteine thiolates for reaction with As (III) is 3-4 Å. This implies that a significant conformational
change in ANT is required for the organoarsenicals to react with cysteines 57 and 257. This conformational change
may relate to the selectivity of the compounds for proliferating cells.
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Background
Healthy cells mainly rely on oxidative phosphorylation
to catabolise glucose, while cancer cells employ aerobic
glycolysis to catabolise both glucose and glutamine [1].
Mitochondria coordinate the catabolism of glucose and
glutamine in cancer cells so targeting this organelle has
potential for the treatment of this disease. A promising
molecular target is the hexokinase II-voltage dependent
anion channel-adenine nucleotide translocase complex
that spans the outer- and inner-mitochondrial mem-
branes. This complex links glycolysis, oxidative phos-
phorylation and mitochondrial-mediated apoptosis in
cancer cells.
The first step in glycolysis, conversion of glucose and
ATP to glucose-6-phosphate (G-6-P) and ADP, is
catalyzed by hexokinase and cancer cells mostly employ
an isoform (HKII) that is bound to mitochondria via
interaction with the outer-membrane voltage dependent
anion channel (VDAC) [2-5]. VDAC is associated with
inner-membrane adenine nucleotide translocase (ANT),
which exchanges matrix ATP for cytosolic ADP across
the inner-membrane [6]. ANT is thought to have two
functions in cancer cells: it provides ATP to hexokinase
II, to phosphorylate and trap glucose in the cell [1], and
is a component of the mitochondrial permeability transi-
tion pore [6], which is involved in the permeability of
the inner-mitochondrial membrane. Opening of this
pore by inactivating ANT allows the equilibration of
solutes <1500 Da in size across the inner-membrane.
This leads to uncoupling of oxidative phosphorylation
and increase in superoxide levels, loss of trans-
membrane potential and decrease in oxygen consump-
tion. These effects of ANT blockade result in
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tic cell death [7].
GSAO (4-(N-(S-glutathionylacetyl)amino) phenylarso-
nous acid) is an ANT inhibitor that is currently being
trialled in a Phase I/IIa dose escalation study in patients
with solid tumours refractory to standard therapy. The
trivalent arsenical of GSAO reacts with ANT in angio-
genic endothelial cells and inhibits tumour angiogenesis
and tumour growth in mice [7]. Metabolism of GSAO
at the cell surface is required for it to exert its anti-
mitochondrial effect. GSAO is first cleaved by g-gluta-
myltranspeptidase at the cell surface to produce GCAO
(4-(N-(S-cysteinylglycylacetyl)amino) phenylarsonous
acid) (Figure 1A). GCAO then enters the cell via an
organic ion transporter and is further processed by
dipeptidases to CAO (4-(N-(S-cysteinylacetyl)amino)
phenylarsonous acid) in the cytosol [8]. CAO enters the
mitochondrial matrix and reacts with ANT. A second
generation ANT inhibitor, PENAO (4-(N-(S-penicillami-
nylacetyl)amino)phenylarsonous acid), has been designed
to bypass the pro-drug processing and metabolism of
GSAO [9]. PENAO is a cysteine mimetic of CAO (Fig-
ure 1A). PENAO accumulates in cells 85-fold faster
than GSAO, which results in a 44-fold increased anti-
proliferative activity and a ~20-fold increased anti-
tumour efficacy in mice. In contrast to GSAO, PENAO
targets both proliferating endothelial and tumour cells.
A Phase I/IIa dose escalation study of PENAO in
patients with solid tumours refractory to standard ther-
apy is currently recruiting. The molecular mechanism of
action of GSAO and PENAO was explored in this study
by identifying the ANT residues that react with the
compounds.
Results and discussion
GSAO, its metabolites GCAO and CAO, and PENAO
triggered permeability transition pore formation in rat
liver mitochondria (Figure 1B). GCAO, CAO and
PENAO were more efficacious than GSAO, possibly
because of their faster entry into mitochondria due to
their smaller size (see Figure 1A). This result indicates
that the arsenic atom of all four compounds reacts with
ANT. Trivalent arsenicals (As(III)) react with closely
spaced protein thiols, forming stable, cyclic dithioarsi-
nite complexes in which both sulphur atoms are bound
to arsenic [10]. We next determined which two ANT
cysteines are cross-linked by the compounds.
Modulating the expression of or mutagenesis of ANT
in mammalian cells is not practical because any disrup-
tion of endogenous ANT leads to perturbation of
Figure 1 GSAO, its metabolites GCAO and CAO, and PENAO trigger opening of the mitochondrial permeability transition pore. A.
Structures of GSAO, its metabolites, and PENAO. L-Glutamyltransferase catalyses the hydrolysis of the peptide bond between GSAO’s L-glutamic
and cysteine residues, while a dipeptidase hydrolyses the peptide bond between GCAO’s glycine and cysteine residues. PENAO is a cysteine
mimetic of CAO. B. Mitochondrial transition pore opening triggered by GSAO, GCAO, CAO and PENAO. Rat liver mitochondria were incubated
with 100 μM of the different compounds and swelling measured by decrease in light scattering at 520 nm over 30 min. The data points and
error bars are the mean ± SD from 4 experiments (performed in duplicate with two different mitochondrial preparations).
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However, mammalian ANT can be expressed and func-
tion in yeast. S. cerevisiae possesses three homologues of
mammalian ANT (Aac1p, Aac2p and Aac3p) and dis-
ruption of one or more of the genes encoding these pro-
teins generates cells that are unable to grow using non-
fermentable sources of carbon, such as glycerol and
ethanol [12]. Mammalian ANT rescues this growth
defect in yeast [13]. To probe the ANT cysteine residues
that GSAO cross-links, human wild-type and cysteine
mutant ANT1 was expressed in S. cerevisiae and binding
of biotin-tagged GSAO and PENAO was measured.
Human ANT1 and the cysteine mutants co-localized
with mitochondrial DNA in the yeast cells, indicating
that the proteins were processed correctly for mitochon-
drial insertion (Figure 2A). The C160A and C257A
ANT1 mutants were also found in the cytoplasm, which
likely represents incomplete or inefficient incorporation
of these mutants into mitochondria. This observation
was confirmed when the mitochondrial fractions from
Figure 2 The trivalent arsenical of GSAO and PENAO reacts with cysteines 57 and 257 of human ANT1. A. Localisation of human ANT1-
GFP in S. cerevisiae. Yeast cells expressing ANT1-GFP and the cysteine mutants were analysed by fluorescence microscopy to determine cellular
localisation. Cells were also stained with DAPI to identify mitochondrial and nuclear DNA. Wild-type and ANT1 cysteine mutants co-localized with
mitochondrial DNA. The C160A and C257A ANT1 mutants were also found in the cytoplasm, which likely represents incomplete or inefficient
incorporation into mitochondria. White arrows indicate the mitochondria (M) or the nucleus (N). B. Mitochondria from S. cerevisiae expressing
ANT1-GFP and the cysteine mutants were isolated and incubated with biotin-tagged GSAO or PENAO. The labelled proteins were collected on
avidin-coated beads and bound ANT1 was detected by Western blot. GSAO- and PENAO-biotin bound to wild-type and C160A mutant ANT1 but
not to C57A and C257A mutants. The human ANT1 and yeast Por1p in the mitochondrial preparations was blotted to show the input protein in
the binding assay. The sizes the proteins in kDa is indicated at left. The results from two separate experiments are shown.
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these mutant proteins in the mitochondria than for the
wild-type and C57A mutant (Figure 2B). Biotin-tagged
GSAO and PENAO clearly bound to wild-type ANT1
and the C160A mutant protein, despite lower levels of
the mutant, but did not appreciably interact with the
C57A or C257A ANT1 mutants (Figure 2B). These
results imply that the arsenic atom of the peptide
arsenicals cross-links cysteine residues 57 and 257 of
ANT. All four isoforms of human ANT (1-4) contain
the same three cysteine residues (residues 57, 160 and
257), so it is likely that the organoarsenicals will react
with all of the human ANTs.
Conclusions
The finding that GSAO and PENAO cross-links Cys57
and Cys257 of ANT is seemingly at odds with the
observation that GSAO binding competes for alkylation
of rat liver ANT by eosine-maleimide [7]. Eosine-malei-
mide alkylates Cys160 in ANT and blocks binding of
the small arsenical, phenylarsine oxide [14]. It is clear
that GSAO- and PENAO-biotin interacts with the
C160A ANT1 mutant, though (Figure 2B). Cross-linking
of Cys57 and Cys257 may sterically block alkylation of
Cys160 by eosine-maleimide, which is a bulky com-
pound with a molecular mass of 743 Da. Conversely,
eosine-maleimide alkylation of Cys160 may block reac-
tion of GSAO or phenylarsine oxide with Cys57 and
Cys257. These scenarios are reasonable considering the
close proximity of the cysteine thiols in the tertiary
structure. The three matrix facing thiols are 18-20 Å
apart in the crystal structures of bovine ANT [15,16]
(Figure 3).
The optimal spacing of cysteine thiolates for reaction
with As(III) is 3-4 Å [17,18]. This implies that a signifi-
cant conformational change in ANT (~15 Å of move-
m e n t )i sr e q u i r e df o rG S A Oa n dP E N A Ot or e a c tw i t h
cysteines 57 and 257. It is possible that the flexibility of
the matrix facing loops relates to the selectivity of
GSAO and PENAO for proliferating cells. The calcium
within the mitochondrial matrix increases several-fold in
proliferating cells [19]. GSAO and PENAO have little
effect on growth quiescent cells [7,9] and the bovine
ANT structure represents the calcium-free form of the
transporter [15,16]. Calcium binding to ANT may influ-
ence its structure and interaction with As(III).
Methods
GSAO [7], GCAO [8], CAO [8], PENAO [9] and biotin-
t a g g e dG S A Oa n dP E N A O[ 7 ]w e r ep r o d u c e da n d
titrated as described.
Expression of human ANT1 in Saccharomyces cerevisiae
For expression of human ANT1 in S. cerevisiae, the cod-
ing sequence of the first 26 amino acid residues from
yeast Aac2p followed by the ANT1 coding sequence was
PCR amplified from y2NHANT1/pRS314 [20] and gate-
way cloned into the yeast expression vector pAG416-
GAL-ccdB-EGFP [21]. In this system, ANT1 is
expressed as a fusion protein with EGFP at the C-termi-
nus under regulation of the GAL1 promoter, which is
repressed by glucose [22]. The ANT1-EGFP construct
has a calculated molecular weight of 62.5 kDa. The
C57A, C160A and C257A mutants of ANT1 were made
using the QuikChange XL Site-Directed Mutagenesis kit
(Integrated Sciences) and their sequence was confirmed.
The wild type ANT1 and mutant constructs were trans-
formed into yeast strain BY4741 (MATa, his3Δ,l e u 2 Δ,
ura3Δ,m e t 1 5 Δ) as described [23]. Yeast transformants
were selected in synthetic complete media lacking uracil
(SC-ura: 20 g/L glucose, 5 g/L ammonium sulphate, 1.7
g/L yeast nitrogen base, 10 mg/L adenine, 50 mg/L argi-
nine, 80 mg/L aspartate, 20 mg/L histidine, 50 mg/L iso-
leucine, 100 mg/L leucine, 50 mg/L lysine, 20 mg/L
methionine, 50 mg/L phenylalanine, 100 mg/L threo-
nine, 100 mg/L tryptophan, 50 mg/L tyrosine and 140
mg/L valine). ANT1-GFP protein was expressed by cul-
turing yeast cells to an optical density of 0.8 at 600 nm
in SC-ura media containing raffinose (20 g/L) instead of
glucose [24]. Cells were cultured for another 6 h with
0.2% galactose before imaging or harvesting the
mitochondria.
Figure 3 Crystal structure of bovine ANT and spacing of the
matrix facing cysteine thiols. A side view of the structure [15] is
shown in part A. The matrix facing cysteine residues are in yellow
space-filling representation. The cysteine numbering is for the
human protein. The corresponding bovine numbering is Cys56,
Cys159 and Cys256. The yellow background represents the
approximate position of the inner-mitochondrial membrane. The
spacing of the three unpaired cysteine residues is shown in part B.
The structures were generated from PDB 1OKC using PyMol [31].
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Cells expressing ANT1-GFP and its mutant forms were
stained with the nucleic acid dye DAPI (5 μg/mL) to
visualize both nuclear and mitochondrial DNA. DAPI
has been mostly used to visualise mitochondria in yeast
cells when the ANT1 homologues (AAC1, AAC2,
AAC3) are over-expressed [25,26]. Over-expression of
ANT1 leads to reduction of mitochondrial membrane
potential, which compromises the effectiveness of mem-
brane potential-sensing dyes such as Mitotracker or rho-
damine 123 [27,28]. Live cells were examined using a
Leica TCS SP5 inverted confocal laser scanning micro-
scope. GFP was excited at 488 nm with fluorescence sig-
nals collected between 520-650 nm. DAPI was excited
by multiphoton at 800 nm with fluorescence signals col-
lected between 405-470 nm. Bright-field and fluorescent
images were collected and processed using ImageJ soft-
ware [29].
Mitochondrial assays
Mitochondria were isolated from the livers of male Wis-
tar rats [7] or BY4741 S. cerevisiae expressing ANT1
[30]. Swelling assays using rat liver mitochondria were
performed as described [7]. S. cerevisiae mitochondria (1
mg/mL in 3 mM Hepes-KOH, pH 7 buffer containing
213 mM mannitol, 71 mM sucrose and 10 mM sodium
succinate) were incubated with 10 μM biotin-tagged
GSAO or PENAO for 1 h at room temperature on a
rotating wheel. The mitochondria were washed 3 times
with the Hepes buffer to remove the unreacted com-
pounds, resuspended in 0.3 mL ice-cold 25 mM Tris,
pH 7.4 buffer containing 140 mM NaCl, 2.7 mM KCl,
0.5% Triton X-100, 0.05% Tween 20, 3 M urea, 5 mM
EDTA and protease inhibitor cocktail (Roche), and incu-
bated with 30 μL streptavidin-dynabeads (Invitrogen) for
2 h at 4°C on a rotating wheel. The beads were washed
5 times with 25 mM Tris, pH 7.4 buffer containing 140
mM NaCl, 0.5% Triton X-100 and 3 M urea and then
resuspended in SDS-PAGE loading buffer containing 20
mM dithiothreitol. Samples were heated at 90°C for 5
min and the eluates resolved on NuPAGE Novex 4-12%
Bis-Tris Gel (Invitrogen) with MOPS running buffer and
transferred to polyvinylidene difluoride membrane. ANT
was detected by Western blot using 1:100 dilution of
anti-human ANT polyclonal antibody Q-18 (Santa
Cruz) and 1:1000 dilution of rabbit anti-goat peroxi-
dase-conjugated antibodies (Dako). The ANT1 and yeast
porin (Por1p) in the mitochondrial preparations was
blotted to show the input protein in the binding assay.
Por1p was detected using 1:5000 dilution of anti- Por1p
monoclonal antibody (Invitrogen) and rabbit anti-mouse
peroxidase-conjugated antibodies (Dako). Chemilumi-
nescence films were analyzed using a GS-700 Imaging
Densitometer and Multi-Analyst software (Bio-Rad, Her-
cules, California).
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